About • Project Farma

Who We Are

We provide biomanufacturing strategy and execution to startup and established pharmaceutical companies, advanced therapy companies, academia, hospitals, government agencies, financial institutions, CROs/CMOs, not-for-profit organizations and medical device companies. Our services include turnkey capital projects, tech transfers and facility builds; owner's representation; project and program management; validation; quality, regulatory and compliance; engineering and automation; serialization / track and trace; reliability, compliance and asset management; and more. We are committed to advancing manufacturing to achieve operational excellence and accelerate speed to market for next-generation medicines.

Our Global Footprint

We provide support globally and are currently supporting projects in: Asia, Australia, Europe, Middle East and North America.

Our corporate headquarters is located in Bethesda, MD and we provide regional support across the United States. We are currently supporting projects in: California, Colorado, Delaware, Florida, Maryland, Massachusetts, Minnesota, New Jersey, New York, North Carolina, Ohio, Oklahoma, Pennsylvania, Texas, Utah, Washington D.C., and Wisconsin.

Philanthropy is Built
into our Foundation

As a patient-focused delivery team, we are committed to connecting our team members to patients and their families. Connecting our team to the patients has fostered a culture within our organization that is focused on providing solutions, meeting deadlines and getting results.

Learn More

Anshul is a biotech entrepreneur, experienced executive, board member, philanthropist and attorney. He is the CEO of Project Farma (“PF”) and President of PerkinElmer OneSource. He is also a board member at the Alliance for Regenerative Medicines, Alliance for mRNA Medicines and IQHQ.

Anshul founded and steered PF to become a prominent global consultancy specializing in advancing manufacturing and technical operations for complex biologics and novel therapies with 200+ professionals. Under Anshul’s guidance, PF pioneered the industrialization of groundbreaking therapeutics, including the first-ever commercially approved cell and gene, radioligand, and RNA-based therapies, and cutting-edge biologics. Additionally, Anshul led M&A for PF, bolstering its ability to offer comprehensive solutions to drug developers facing manufacturing challenges. PF’s achievements include leading 100+ facility builds with a total capital investment exceeding $6BB, managing 400+ capital projects, and collaborating with 100+ life science companies.

In 2020, Precision Medicine Group (PMG) acquired PF, making it a key part of Precision’s integrated services focused on research and clinical development, regulatory, manufacturing, and commercial needs to bring transformative therapies to market. Anshul also developed Precision ADVANCE, a collection of interconnected services within PMG focused on successfully bringing cell or gene therapies to market and served as its President from 2020-2024. In 2025, PerkinElmer acquired PF, expanding PerkinElmer’s OneSource Professional Services offering for the life sciences industry.

Anshul’s commitment to advancing next-generation medicines extends past PF to various boards and philanthropic organizations, including IQHQ, Alliance for Regenerative Medicines, Alliance for mRNA Medicines, Institute for Life Changing Medicines and several patient-advocacy organizations.

Before his tenure at PF, Anshul was an attorney and founded several digital agencies. He was a patent litigator at Jones Day and dedicated pro bono work to help persecuted refugees attain asylum in the United States. He graduated from Purdue University with a Bachelor’s in Computer and Electrical Engineering and earned his law degree from John Marshall Law School. During law school, he clerked for a federal judge in the Northern District of Illinois and was Editor-in-Chief of the Review of Intellectual Property Law.

As a PMI-certified Project Management Professional (PMP) with 25 years of experience, Chip has seamlessly transitioned between pharmaceutical and regulated non-pharmaceutical industries, including a blend of owner companies, services providers, and consulting companies.

Chip has broad-based experience with validation of facilities, utilities, and equipment; computer system validation; process validation; and cleaning validation. This experience includes manufacturing, packaging, and laboratory facilities; critical utilities; aseptic processes and sterile filling; oral solid dose manufacturing; packaging systems; environmental chambers; and warehouses. As a quality consultant, Chip has experience with quality systems, quality risk management, risk assessment, root cause analysis, change control, CAPA, and failure investigation. He has managed facility qualification and cleaning validation projects for clients in the medical device and regulated non-pharmaceutical industries.

Chip has a degree in Chemical Engineering from Rose-Hulman Institute of Technology and is very active in ISPE. He co-authored the Good Engineering Practice Good Practice Guide (2021), is a contributing author of the upcoming Validation 4.0 Good Practice Guide, author of several articles in Pharmaceutical Engineering, a member of the C&Q and Pharma 4.0 Communities of Practice, and a qualified instructor in three courses: Risk-Based C&Q, Good Engineering Practice, and Fundamentals of GMPs.